242 related articles for article (PubMed ID: 37665349)
21. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.
Van Etten RA; Koschmieder S; Delhommeau F; Perrotti D; Holyoake T; Pardanani A; Mesa R; Green T; Ibrahim AR; Mughal T; Gale RP; Goldman J
Haematologica; 2011 Apr; 96(4):590-601. PubMed ID: 21242185
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.
Vannucchi AM; Pieri L; Susini MC; Guglielmelli P
Future Oncol; 2012 May; 8(5):575-93. PubMed ID: 22646772
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Mughal TI; Gotlib J; Mesa R; Koschmieder S; Khoury HJ; Cortes JE; Barbui T; Hehlmann R; Mauro M; Saussele S; Radich JP; Van Etten RA; Saglio G; Verstovek S; Gale RP; Abdel-Wahab O
Leuk Res; 2018 Apr; 67():67-74. PubMed ID: 29466766
[TBL] [Abstract][Full Text] [Related]
24. Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
Kim HR; Choi HJ; Kim YK; Kim HJ; Shin JH; Suh SP; Ryang DW; Shin MG
PLoS One; 2013; 8(1):e52518. PubMed ID: 23349688
[TBL] [Abstract][Full Text] [Related]
25. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
Barosi G; Tefferi A; Besses C; Birgegard G; Cervantes F; Finazzi G; Gisslinger H; Griesshammer M; Harrison C; Hehlmann R; Hermouet S; Kiladjian JJ; Kröger N; Mesa R; Mc Mullin MF; Pardanani A; Passamonti F; Samuelsson J; Vannucchi AM; Reiter A; Silver RT; Verstovsek S; Tognoni G; Barbui T
Leukemia; 2015 Jan; 29(1):20-6. PubMed ID: 25151955
[TBL] [Abstract][Full Text] [Related]
26. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
Takenaka K
Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
[TBL] [Abstract][Full Text] [Related]
28. Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm.
Kim N; Kim IS; Chang CL; Kang JE; Lee EY; Shin HJ
Ann Lab Med; 2015 May; 35(3):348-51. PubMed ID: 25932444
[TBL] [Abstract][Full Text] [Related]
29. A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.
Mambet C; Matei L; Necula LG; Diaconu CC
J Immunoassay Immunochem; 2016; 37(4):331-45. PubMed ID: 26890068
[TBL] [Abstract][Full Text] [Related]
30. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
[TBL] [Abstract][Full Text] [Related]
31. Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.
Ramakrishnan A; Sandmaier BM
Expert Rev Hematol; 2010 Feb; 3(1):23-33. PubMed ID: 20383269
[TBL] [Abstract][Full Text] [Related]
32. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
Ma W; Kantarjian H; Zhang X; Wang X; Zhang Z; Yeh CH; O'Brien S; Giles F; Bruey JM; Albitar M
PLoS One; 2010 Aug; 5(8):e12165. PubMed ID: 20730051
[TBL] [Abstract][Full Text] [Related]
33. Co-occurrence of
Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of Korean BCR-ABL1-Negative Myeloproliferative Neoplasms Related to the 2016 WHO Criteria Revision.
Kim N; Park H; Shin S; Yoon JH; Roh EY
Clin Lab; 2022 Sep; 68(9):. PubMed ID: 36125143
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic complexity in myeloproliferative neoplasms.
Cross NC
Hematology Am Soc Hematol Educ Program; 2011; 2011():208-14. PubMed ID: 22160036
[TBL] [Abstract][Full Text] [Related]
36. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.
Griesshammer M; Sadjadian P; Wille K
Expert Rev Hematol; 2018 Sep; 11(9):697-706. PubMed ID: 30084669
[TBL] [Abstract][Full Text] [Related]
37. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.
Guy A; Poisson J; James C
Leukemia; 2021 Apr; 35(4):935-955. PubMed ID: 33658660
[TBL] [Abstract][Full Text] [Related]
39. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
40. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
